Cannabis Bioscience Revenue Plunges 67% to $88,671 in Nine Months Ending February 2026
Cannabis Bioscience International Holdings, a cannabis-focused company, reported revenue of $88,671 for the nine months ending February 28, 2026, down 67% from $268,066 in the year-ago period. The company posted a net loss of $303,546.
Cannabis Bioscience International Holdings, a cannabis-focused company, reported revenue of $88,671 for the nine months ending February 28, 2026, down 67% from $268,066 in the year-ago period. The company posted a net loss of $303,546 for the nine-month period, compared with a loss of $337,076 a year earlier. Read more earnings reports.
For the three months ending February 28, 2026, revenue dropped 25% to $11,205 from $14,931 in the prior-year quarter. The quarterly net loss narrowed to $103,933 from $181,243 a year earlier.
Operating expenses for the nine-month period totaled $330,903, down 36% from $518,970 in the prior-year period. Labor and related expenses fell to $116,526 from $145,551. The company reported an operating loss of $263,920 for the nine months, compared with an operating loss of $286,465 a year earlier.
Gross profit for the nine-month period reached $66,983, down 71% from $232,505 in the year-ago period. Cost of revenue fell to $21,688 from $35,561.
The company's balance sheet showed total assets of $1,544 as of February 28, 2026, down sharply from $31,880 as of May 31, 2025. Cash holdings stood at $90, down from $12,952 at the prior fiscal year-end. Accounts receivable declined to $1,266 from $6,380.
Total liabilities increased to $1,468,674 from $1,195,463 at the prior fiscal year-end. The company carried long-term debt of $249,500, unchanged from May 31, 2025. Current liabilities rose to $1,219,174 from $945,963.
Stockholders' deficit widened to $1,467,130 from $1,163,583 as of May 31, 2025. Retained deficit stood at $6,186,448, compared with $5,882,901 at the prior fiscal year-end. The company had 11,626,749,347 common shares outstanding as of February 28, 2026.
Cash used in operations totaled $123,802 for the nine months ending February 28, 2026, compared with $185,315 in the year-ago period. Cash from financing activities provided $110,940, versus $185,108 a year earlier.
The company reported a basic and diluted loss per share of $0.000026 for the nine-month period, compared with $0.0000032 in the prior-year period. Weighted average shares outstanding increased to 11,626,749,347 from 10,573,938,169.
| Metric | 9 Months Ending Feb 28, 2026 | 9 Months Ending Feb 28, 2025 |
|---|---|---|
| Revenue | $88,671 | $268,066 |
| Gross Profit | $66,983 | $232,505 |
| Operating Loss | ($263,920) | ($286,465) |
| Net Loss | ($303,546) | ($337,076) |
| Loss Per Share | ($0.000026) | ($0.0000032) |
| Total Assets | $1,544 | $31,880* |
| Cash | $90 | $12,952* |
| Total Liabilities | $1,468,674 | $1,195,463* |
*As of May 31, 2025